Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

This study is testing CAR-NK cell therapy — a cutting-edge immune cell treatment — for women with ovarian cancer that has come back or stopped responding to standard treatments. The engineered cells are designed to recognize and attack ovarian cancer cells by targeting multiple proteins found on their surface. **You may be eligible if...** - You have been diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer (especially high-grade serous type) - Your cancer has returned or stopped responding after at least 2 prior treatment regimens, including platinum-based chemotherapy - Your tumor tests positive for at least two of the following proteins: MSLN, FRalpha (FOLR1), or MUC16 - You are in good physical condition (ECOG 0–1) with adequate blood, liver, and kidney function - You are willing to use contraception for 12 months after treatment **You may NOT be eligible if...** - You received CAR-T or CAR-NK cell therapy in the past 6 months - Your cancer has spread to the brain - You have an uncontrolled infection, active tuberculosis, or uncontrolled HIV/hepatitis - You have serious heart disease or active autoimmune disease requiring medication - You had major surgery in the past 4 weeks Talk to your doctor to see if this trial is right for you.